Literature DB >> 27338590

Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy.

Masakazu Hori1, Masanori Someya2, Yoshihisa Matsumoto3, Kensei Nakata2, Mio Kitagawa2, Tomokazu Hasegawa2, Takaaki Tsuchiya2, Yuki Fukushima2, Toshio Gocho2, Yasushi Sato4, Hiroyuki Ohnuma4, Junji Kato4, Shintaro Sugita5, Tadashi Hasegawa5, Koh-Ichi Sakata2.   

Abstract

DNA double-strand break (DSB) is one of the most serious forms of damage induced by ionizing irradiation and is mainly repaired by the non-homologous end joining (NHEJ) repair. Immunohistochemical analysis of proteins involved in NHEJ, such as XRCC4 (X-ray repair cross-complementing protein 4), Ku86 and DNA-PKcs (DNA-dependent protein kinase, catalytic subunits), may be useful for predicting tumor radiosensitivity. We examined 92 patients with esophageal squamous cell carcinoma (ECSS) who were treated by radiotherapy between 1999 and 2008. Immunohistochemical examination of tumor tissue for Ki-67 and DSB-related proteins, including XRCC4, Ku86, and DNA-PKcs, was performed using pretreatment biopsy specimens. Low expression of XRCC4 was detected in 31 of 92 examined samples (33.7 %). The 5-year overall survival (OS) rate was 67.7 % in the low expression group and 31.0 % in the high expression group (P = 0.00). Multivariate analysis confirmed that advanced T-stage (HR 3.24, P = 0.01), radiation dose less than 66 Gy (HR 2.23, P = 0.02), absence of systemic chemotherapy (HR 2.59, P = 0.05), and high expression of XRCC4 (HR 12.0, P = 0.02) were independent prognostic factors for predicting poor OS. Other DSB-related proteins and Ki-67 were not predictive factors. XRCC4 expression might have an influence on results of radiotherapy for patients with ESCC.

Entities:  

Keywords:  DNA-PKcs; Esophageal squamous cell carcinoma; Immunohistochemical staining; Ku86; Radiotherapy; XRCC4

Mesh:

Substances:

Year:  2016        PMID: 27338590     DOI: 10.1007/s00795-016-0144-5

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  20 in total

1.  Results of external irradiation and low-dose-rate intraluminal brachytherapy for esophageal cancer.

Authors:  Masanori Someya; Koh-ichi Sakata; Akio Saito; Hisayasu Nagakura; Atsushi Oouchi; Masato Hareyama
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

2.  Gene expression associated with DNA-dependent protein kinase activity under normoxia, hypoxia, and reoxygenation.

Authors:  Tadashi Tsuchimoto; Koh-ichi Sakata; Masanori Someya; Hiroyuki Yamamoto; Ryoichi Hirayama; Yoshihisa Matsumoto; Yoshiya Furusawa; Masato Hareyama
Journal:  J Radiat Res       Date:  2011       Impact factor: 2.724

3.  Radiation-induced XRCC4 association with chromatin DNA analyzed by biochemical fractionation.

Authors:  Radhika Pankaj Kamdar; Yoshihisa Matsumoto
Journal:  J Radiat Res       Date:  2010-04-24       Impact factor: 2.724

4.  The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer.

Authors:  Harushi Udagawa; Masaki Ueno; Hisashi Shinohara; Shusuke Haruta; Sachiko Kaida; Masatoshi Nakagawa; Masahiko Tsurumaru
Journal:  J Surg Oncol       Date:  2012-04-13       Impact factor: 3.454

Review 5.  Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications.

Authors:  Sophie E Polo; Stephen P Jackson
Journal:  Genes Dev       Date:  2011-03-01       Impact factor: 11.361

6.  Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

Authors:  Nobutoshi Ando; Toshifumi Iizuka; Hiroko Ide; Kaoru Ishida; Masayuki Shinoda; Tadashi Nishimaki; Wataru Takiyama; Hiroshi Watanabe; Kaichi Isono; Norio Aoyama; Hiroyasu Makuuchi; Otsuo Tanaka; Hideaki Yamana; Shunji Ikeuchi; Toshiyuki Kabuto; Kagami Nagai; Yutaka Shimada; Yoshihide Kinjo; Haruhiko Fukuda
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

7.  A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.

Authors:  Yasushi Sato; Tetsuji Takayama; Tamotsu Sagawa; Tetsuro Okamoto; Koji Miyanishi; Tsutomu Sato; Hironobu Araki; Satoshi Iyama; Seiichiro Abe; Kazuyuki Murase; Rishu Takimoto; Hisayasu Nagakura; Masato Hareyama; Junji Kato; Yoshiro Niitsu
Journal:  Cancer Chemother Pharmacol       Date:  2006-02-04       Impact factor: 3.333

8.  The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma.

Authors:  Yasuhiro Komuro; Toshiaki Watanabe; Yoshio Hosoi; Yoshihisa Matsumoto; Keiichi Nakagawa; Nelson Tsuno; Shinsuke Kazama; Joji Kitayama; Norio Suzuki; Hirokazu Nagawa
Journal:  Cancer       Date:  2002-09-15       Impact factor: 6.860

9.  Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas.

Authors:  Y Okuno; Y Nishimura; I Kashu; K Ono; M Hiraoka
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

10.  Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer.

Authors:  C Beskow; L Kanter; A Holgersson; B Nilsson; B Frankendal; E Avall-Lundqvist; R Lewensohn
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

View more
  5 in total

1.  Prediction of Results of Radiotherapy With Ku70 Expression and an Artificial Neural Network.

Authors:  Tomokazu Hasegawa; Masanori Someya; Masakazu Hori; Takaaki Tsuchiya; Yuuki Fukushima; Yoshihisa Matsumoto; Koh-Ichi Sakata
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

2.  Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells.

Authors:  Yuqing Wen; Gongpeng Dai; Liping Wang; Kanda Fu; Shuguang Zuo
Journal:  Biosci Rep       Date:  2019-03-19       Impact factor: 3.840

3.  Evaluation of X-Ray Repair Cross-Complementing Family Members as Potential Biomarkers for Predicting Progression and Prognosis in Hepatocellular Carcinoma.

Authors:  Jie Mei; Huiyu Wang; Runjie Wang; Jiadong Pan; Chaoying Liu; Juanying Xu
Journal:  Biomed Res Int       Date:  2020-03-17       Impact factor: 3.411

4.  The XRCC4 rs1805377 polymorphism is not associated with the risk of cancer: An updated meta-analysis.

Authors:  Xin-Yuan Zhang; Xiao-Han Wei; Bao-Jie Wang; Jun Yao
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

5.  Prognostic significance of XRCC4 expression in hepatocellular carcinoma.

Authors:  Jun Lu; Xing-Zhizi Wang; Tian-Qi Zhang; Xiao-Ying Huang; Jin-Guang Yao; Chao Wang; Zhong-Hong Wei; Yun Ma; Xue-Min Wu; Chun-Ying Luo; Qiang Xia; Xi-Dai Long
Journal:  Oncotarget       Date:  2017-09-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.